Clinical Efficacy of Levosimendan in the Treatment of Heart Failure and its Effect on Cardiac Function and Inflammatory Response in Patients with Heart Failure
Objective To investigate the clinical efficacy of levosimendan (LS) in the treatment of heart failure (HF). Methods From September 2021 to August 2023,68 patients with HF admitted to Yudu County People's Hospital were selected and divided into conventional group (34 patients) and LS group (34 patients) by random number table method. The conventional group was treated with conventional anti-heart failure treatment,and the LS group was treated with levosimendan on the basis of the control group. The clinical efficacy,cardiac function indexes[left ventricular ejection fraction (LVEF),mitral early diastolic blood flow velocity/late diastolic blood flow velocity (E/A)],inflammatory factors[high-sensitivity C-reactive protein (hs-CRP),tumor necrosis factor-α (TNF-α)],6 min walking distance (6MWD),and heart failure symptom status questionnaire (SSQ-HF) scores were compared between the two groups.Results The total effective rate of the LS group was higher than that of the conventional group (P<0.05). Compared with before treatment,LVEF and E/A in the two groups increased after treatment (P<0.05),hs-CRP and TNF-αdecreased (P<0.05),and LVEF and E/A in the LS group were higher than those in the conventional group (P<0.05),hs-CRP and TNF-αwere lower than those in the conventional group (P<0.05). Compared with before treatment,the 6MWD result of the two groups was improved one month after treatment,and the SSQ-HF scores were decreased (P<0.05). The 6MWD result of the LS group was greater than those of the conventional group,and the SSQ-HF score was lower than that of the conventional group (P<0.05).Conclusion Levosimendan is effective in the treatment of HF. It can improve the cardiac function of patients,down-regulate the body's inflammatory response,and relieve the symptoms of heart failure. It is worthy of clinical application.
万方数据
维普
